BamSEC and AlphaSense Join Forces
Learn More

Tempest Therapeutics Inc.

NASDAQ: TPST    
Share price (7/10/25): $7.36    
Market cap (7/10/25): $27.1 million

Material Contracts Filter

EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.12
from 10-K/A 8 pages January 12, 2022 via Email Only Swhiting@tempesttx.com Sam Whiting, M.D., PH.D. Re: Executive Employment Agreement Dear Sam
12/34/56
EX-10.11
from 10-K/A 9 pages January 12, 2022 via Email Only Sbrady@tempesttx.com Mr. Stephen R. Brady Chief Executive Officer Re: Executive Employment Agreement Dear Steve
12/34/56
EX-10.33
from 10-K 9 pages January 1, 2025 Nicholas Maestas Re: Executive Employment Agreement
12/34/56
EX-10.32
from 10-K 16 pages Master Clinical Supply Agreement
12/34/56
EX-10.1
from 10-Q 11 pages Via Email Only [Redacted] Tom Dubensky, PH.D. Re: Separation and Consulting Agreement Dear Tom: This Letter Sets Forth the Substance of the Separation and Consulting Agreement (The “Agreement”) That Tempest Therapeutics, Inc. (The “Company”) Is Offering to You to Aid in Your Employment Transition. 1. Separation. Your Last Day of Work With the Company and Your Employment Termination Date Will Be September 15, 2023 (The “Separation Date”). 2
12/34/56
EX-10.4
from 10-Q 10 pages Tempest Therapeutics, Inc. Inducement Grant Outside of Amended and Restated 2019 Equity Incentive Plan
12/34/56
EX-10.3
from 10-Q 24 pages Tempest Therapeutics, Inc. 2023 Inducement Plan Adopted by the Board of Directors: June 21, 2023
12/34/56
EX-10.2
from 10-Q 10 pages Tempest Therapeutics, Inc. Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 25 pages Tempest Therapeutics, Inc. Amended and Restated 2023 Equity Incentive Plan Approved by the Board of Directors: April 28, 2023 (The “Adoption Date”) Approved by the Stockholders: June 15, 2023
12/34/56
EX-10
from 10-K 64 pages The Towers at Sierra Point Lease
12/34/56
EX-10.1
from 10-Q 4 pages Written Agreement & Consent of Warrant Holders and Tempest Therapeutics, Inc
12/34/56
EX-10.5
from 10-Q 4 pages Agreement for Termination of Lease and Voluntary Surrender of Premises
12/34/56
EX-10.2
from 8-K 11 pages Tempest Therapeutics, Inc. Amended and Restated 2019 Employee Stock Purchase Plan as Amended and Restated by the Board of Directors: April 22, 2022 Approved by the Stockholders: June 17, 2022
12/34/56
EX-10.1
from 8-K 29 pages Tempest Therapeutics, Inc. Amended and Restated 2019 Equity Incentive Plan as Amended and Restated by the Board of Directors: April 22, 2022 Approved by the Stockholders: June 17, 2022
12/34/56
EX-10.4
from 10-Q 8 pages January 12, 2022 via Email Only Nmaestas@tempesttx.com Nicholas M. Maestas Re: Executive Employment Agreement
12/34/56
EX-10.3
from 10-Q 8 pages January 12, 2022 via Email Only Swhiting@tempesttx.com Sam Whiting, M.D., PH.D. Re: Executive Employment Agreement
12/34/56
EX-10.2
from 10-Q 8 pages January 12, 2022 via Email Only Tdubensky@tempesttx.com Tom Dubensky, PH.D. Re: Executive Employment Agreement
12/34/56
EX-10.1
from 10-Q 8 pages January 12, 2022 via Email Only Sbrady@tempesttx.com Mr. Stephen R. Brady Chief Executive Officer Re: Executive Employment Agreement
12/34/56
EX-10.2
from 8-K 20 pages Registration Rights Agreement
12/34/56